An Extension Study of ANAVEX2-73 in Patients With Mild to Moderate Alzheimer's Disease
NCT ID: NCT02756858
Last Updated: 2021-01-12
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
21 participants
INTERVENTIONAL
2016-03-31
2020-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
OLE of Phase 2b/3 Study ANAVEX2-73-AD-004
NCT04314934
Phase 2a Dose Finding, PK/PD and 12 Month Exploratory Efficacy Study of ANAVEX2-73 in Patients With Alzheimer's Disease
NCT02244541
ANAVEX2-73 for Treatment of Early Alzheimer's Disease
NCT03790709
Clinical Trial of CT1812 in Mild to Moderate Alzheimer's Disease
NCT02907567
Study of LY2886721 in Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease
NCT01561430
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
ANAVEX2-73 Oral as assigned in ANAVEX2-73-002
ANAVEX2-73
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
ANAVEX2-73
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
55 Years
85 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Anavex Life Sciences Corp.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Melbourne Health - The Royal Melbourne Hospital
Melbourne, Victoria, Australia
Austin Health - Heidelberg Repatriation Hospital
Melbourne, Victoria, Australia
Caulfield Hospital
Melbourne, Victoria, Australia
Nucleus Network- Centre for Clinical Studies
Melbourne, Victoria, Australia
St. Vincent's Hospital
Melbourne, Victoria, Australia
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Hampel H, Williams C, Etcheto A, Goodsaid F, Parmentier F, Sallantin J, Kaufmann WE, Missling CU, Afshar M. A precision medicine framework using artificial intelligence for the identification and confirmation of genomic biomarkers of response to an Alzheimer's disease therapy: Analysis of the blarcamesine (ANAVEX2-73) Phase 2a clinical study. Alzheimers Dement (N Y). 2020 Apr 19;6(1):e12013. doi: 10.1002/trc2.12013. eCollection 2020.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ANAVEX2-73-003
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.